Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN) (BEN)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02404155 |
Recruitment Status :
Completed
First Posted : March 31, 2015
Results First Posted : January 31, 2023
Last Update Posted : January 31, 2023
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Schizophrenia | Drug: Clozapine | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 274 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN) |
Actual Study Start Date : | July 2015 |
Actual Primary Completion Date : | October 26, 2021 |
Actual Study Completion Date : | October 26, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: Clozapine |
Drug: Clozapine |
- Change in White Blood Cell (WBC) (mm3) and Absolute Neutrophil Counts (ANC) (mm3) in Persons According to Presence of the DARC Null Allele. [ Time Frame: 24 week period baseline and endpoint ]
- Number of Episodes of Agranulocytosis (Count). [ Time Frame: 6 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 64 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
- Eligible and recommended for clozapine treatment (e.g. treatment resistant schizophrenia, schizoaffective disorder, bipolar disorder, other psychotic disorder, delusional disorder, hostility, other documented rationale)
- Male or Female
- African Ancestry (African, African-American or African-Caribbean). This population will make up the majority of the study. However, there are cases of BEN in individuals of Middle Eastern, Caucasian, and other ethnicity. The investigators will accept these patients as they may have unknown African ancestry and genotyping will be important.
- Age: 18 to 64 years.
- History of a low absolute neutrophil count (ANC<2500 cells/mm3 in past 24 months)
- Documented ability to sign informed consent. This is a score of ≥10/12 on ESC.
- Effective birth control if of child bearing potential
Exclusion Criteria
- DSM-IV diagnosis of Mental Retardation
- Pregnancy or lactation
- History of myeloproliferative disorder
- Uncontrolled seizure disorder
- History of paralytic ileus
- History of clozapine-induced ANC < 700 mm3
- Systemic Lupus Erythematosus, Multiple Sclerosis, Hashimoto's Thyroiditis, Sjogren's Syndrome, Grave's Disease*
- Medical condition whose pathology or treatment would likely alter the presentation or treatment of schizophrenia or significantly increase the risks associated with the proposed protocol.
- Medical condition affecting patient's ability to mount an immune response
- Current bacterial or viral infection*
- Sickle cell anemia
- Positive for bacteria in urine culture*
- Temperature > 37.5 º Celsius, 99.5 º Fahrenheit*
- Current treated or untreated cancer*
- Documented nutritional deficiencies (such as Beriberi, Pellagra, Rickets, Scurvy, Keshan Disease)*
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02404155
United States, Maryland | |
Maryland Psychiatric Research Center | |
Catonsville, Maryland, United States, 21228 |
Principal Investigator: | Deanna L Kelly, Pharm.D, BCPP | Principal Investigator |
Documents provided by Deanna Kelly, University of Maryland, Baltimore:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Deanna Kelly, Principal Investigator, University of Maryland, Baltimore |
ClinicalTrials.gov Identifier: | NCT02404155 |
Other Study ID Numbers: |
HP-00063484 |
First Posted: | March 31, 2015 Key Record Dates |
Results First Posted: | January 31, 2023 |
Last Update Posted: | January 31, 2023 |
Last Verified: | January 2023 |
Neutropenia Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Agranulocytosis Leukopenia Cytopenia Hematologic Diseases Leukocyte Disorders Clozapine Serotonin Antagonists |
Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs GABA Antagonists GABA Agents |